Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced presentations by Dr. Sean Tucker and Dr. James F. Cummings at the World Vaccine Congress Washington 2023 on April 5 and 6, 2023. Dr. Tucker will discuss advancements in oral tablet vaccinations aimed at blocking transmission and enhancing existing vaccines on April 5 at 4:40 p.m. ET. Dr. Cummings will present findings on Vaxart’s oral bivalent norovirus vaccine candidate on April 6 at 12:15 p.m. ET. Vaxart is a clinical-stage biotechnology company focusing on oral recombinant vaccines that do not require refrigeration.

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023.

Presentation Information:

Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination
Speaker: Dr. Sean Tucker
Date: Wednesday, April 5, 2023
Time: 4:40 p.m. ET

Title: Potent serum and mucosal immune responses to norovirus with Vaxart’s oral bivalent norovirus vaccine candidate
Speaker: Dr. James F. Cummings
Date: Thursday, April 6, 2023
Time: 12:15 p.m. ET

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts 

Vaxart Media Relations:	Investor Relations:
Mark Herr	Andrew Blazier
Vaxart, Inc.	FINN Partners
mherr@vaxart.com	IR@Vaxart.com
(203) 517-8957	(646) 871-8486

FAQ

What presentations will Vaxart make at the World Vaccine Congress Washington 2023?

Vaxart will present two topics: Dr. Sean Tucker will discuss oral tablet vaccinations on April 5, 2023, and Dr. James F. Cummings will present on the bivalent norovirus vaccine candidate on April 6, 2023.

When and where is Vaxart presenting their vaccine research?

Vaxart is presenting at the World Vaccine Congress in Washington, D.C., on April 5 and 6, 2023.

What time is Dr. Sean Tucker's presentation at the Congress?

Dr. Sean Tucker's presentation is scheduled for April 5, 2023, at 4:40 p.m. ET.

What time will Dr. James F. Cummings speak at the World Vaccine Congress?

Dr. James F. Cummings will present at 12:15 p.m. ET on April 6, 2023.

What is Vaxart's focus in vaccine development?

Vaxart focuses on developing oral recombinant vaccines for various viruses that can be stored without refrigeration.